Navigation Links
Shire Proposes to Expand Specialist Gastrointestinal Portfolio
Date:8/3/2010

">EUR328 million). The acquisition will be funded out of Shire's current cash resources.

It is anticipated that the offer to Movetis' shareholders will open for acceptance in September. The offer is contingent upon the fulfillment of certain conditions, including receipt of acceptances in respect of at least 90% of the shares that are the subject of the offer and that Movetis does not suffer a material adverse change before the results of the offer are published.

Shire has entered into agreements with institutional shareholders in which they have unconditionally committed 38.9% of Movetis' existing ordinary share capital to the offer.

Once finalized, the prospectus will be published and circulated to Movetis' shareholders, and details will be available on www.shire.com and www.movetis.com. No action will be taken to permit a public tender offer in any other jurisdiction than Belgium. This press release does not constitute an invitation to sell or the solicitation of an offer to buy any security.

Deutsche Bank AG is acting as financial adviser to Shire.

Strategic Rationale for the Transaction

The acquisition adds to Shire's portfolio of treatments for GI conditions with high unmet need and prescribed by specialist physicians. Shire's stated strategic focus on GI led to the establish
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Lialda(R) - Shire Files Suit Against Cadila Healthcare Limited, Doing Business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.
2. Shire Receives CHMP Positive Opinion for VPRIV(TM) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union
3. Shire plc Appoints Two New Board Directors
4. INTUNIV(TM) - Shire Files Suit Against Anchen Pharmaceuticals, Inc. and Anchen, Inc.
5. Shire Receives 2010 Corporate Award From the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for Injection)
6. INTUNIV(TM) - Shire Files Suit Against Actavis Elizabeth LLC and Actavis Inc.
7. Shires Replenished Portfolio Drives Excellent Quarterly Performance
8. Shire Receives INTUNIV (TM) Paragraph IV Notice Letter From Teva Pharmaceuticals
9. Shire Supports Rare Disease Day 2010
10. Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
11. Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL(R) (agalsidase alfa) With the U.S. Food and Drug Administration (FDA)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Dr. Ingrid Warmuth and Anamaria Newport, MHS, PA-C, with locations ... an Open House at their Swedesboro location, 95 Woodstown Road. ... 10 AM to 2 PM. , During the open ... be on hand to talk to people about the benefits ... cosmetic consultations. There will also be specials offered, such as ...
(Date:5/24/2013)... Israel , May 24, 2013 ... leader in embolic protection stents, announced that Alan ... and Craig Shore , the Company,s Chief ... Investor Conference on Thursday May 30, 2013 at The Pfister ... The format of the conference includes a ...
(Date:5/24/2013)... 24, 2013 Many factors impact tissues ... or efflux transporters at the blood-tissue barrier. Even when ... unbound fractions in the tissue rather than the total ... challenges is required to guide lead optimization, predict in ... species-dependent variables that may impact the likely human clinical ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Quincy ... discovery and development of calcium-binding proteins to support ... safety assessment study of apoaequorin in ... journal published for the British Industrial Biological Research ... was to investigate potential adverse effects, if any, ...
Breaking Biology Technology:InspireMD To Participate In Benchmark Investor Conference On May 30th 2InspireMD To Participate In Benchmark Investor Conference On May 30th 3InspireMD To Participate In Benchmark Investor Conference On May 30th 4DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2
... premiered this week a new Mediasite ... audience on the Internet interested in multimedia presentations featuring ... presentations by users of the companys rich media software ... with other media sources slideshows and text. The site ...
... the service they are getting, a Consumer Reports survey shows. ... "dead" zones, dropped calls and more, and ended up finding ... in consumer's minds. , ,And to top it off, almost ... services. , ,Verizon came out on top in satisfaction in ...
... took place this past week at the University of Chicagos ... of the meeting was an opportunity to hear from four ... BIO meetings in different cities, as a preview to what ... of Biotechnology meeting comes to Chicago in April, 2006. , ...
Cached Biology Technology:Sonic Foundry creates search engine for 7,000 expert video presentations 2The legacy of BIO 2006, what it will be and how we need to plan for it now 2The legacy of BIO 2006, what it will be and how we need to plan for it now 3The legacy of BIO 2006, what it will be and how we need to plan for it now 4The legacy of BIO 2006, what it will be and how we need to plan for it now 5The legacy of BIO 2006, what it will be and how we need to plan for it now 6
(Date:5/22/2013)... A new, streamlined approach to genetic engineering drastically ... new genes into bacteria, the workhorses of biotechnology, ... ACS Synthetic Biology , the method paves the ... for drug development, environmental cleanup and other activities. ... or integrating, a piece of the genetic material ...
(Date:5/22/2013)... whole organism, as they may lead to life-threatening illnesses ... report how byproducts of respiration cause mispairing of subunits ... cells controls the form and function of every cell ... encoded in the linear sequence of the four subunits ... guanine (G) and thymine (T). Random changes in the ...
(Date:5/22/2013)... new details on how climate change will affect interactions ... the Journal of Animal Ecology . This knowledge, ... informing policymakers of how species are likely to be ... a growing recognition among biologists that climate change is ... this is going to have very important consequences for ...
Breaking Biology News(10 mins):DNA damage: The dark side of respiration 2UCLA life scientists present new insights on climate change and species interactions 2UCLA life scientists present new insights on climate change and species interactions 3UCLA life scientists present new insights on climate change and species interactions 4UCLA life scientists present new insights on climate change and species interactions 5
... CA--The four largest nonprofit plant science research institutions in ... of Independent Plant Research Institutes (AIPI) in an effort ... challenges facing society in a more coordinated and rapid ... Institute for Plant Research (Cornell University), The Carnegie Institution ...
... the most recent, popular supplements for athletes looking to boost ... called L-arginine. The reason for its popularity is ... "First, L-arginine is a precursor for nitric oxide that ... aid the delivery of important nutrients to working muscles and ...
... was random, regulated, double-blinded and broad-based. The drug was tested ... Type 1 diabetes a short time before joining the trial. ... Europe, Israel and South Africa. The patients in the trial ... the trial drug (DiaPep277) through a subcutaneous injection once every ...
Cached Biology News:Big boost to plant research 2Big boost to plant research 3L-arginine: Supplement tested on fit, athletic men shows no advantage 2L-arginine: Supplement tested on fit, athletic men shows no advantage 3Andromeda Biotech: A drug for type 1 diabetes 2